Rigel Pharmaceuticals Appoints New Chief Medical Officer, Former CMO Departs
RIGL has more than doubled off its 52-week low of $18.24.
Summary
Rigel Pharmaceuticals announced a leadership change in its medical department, with Dr. Alison L. Hannah appointed as the new Executive Vice President and Chief Medical Officer, succeeding Dr. Lisa Rojkjaer.
Key Events · Executive and Board Changes · RIGL
-
Chief Medical Officer Change
Dr. Lisa Rojkjaer ceased serving as Executive Vice President and Chief Medical Officer of the Company, effective June 25, 2026.
-
New CMO Appointed
Dr. Alison L. Hannah was appointed Executive Vice President and Chief Medical Officer, effective July 1, 2026.
-
Board Resignation
Dr. Hannah resigned from the Company's Board of Directors, effective July 1, 2026, concurrent with her appointment as CMO.
Analysis · RIGL · Life Sciences
This 8-K reports a significant executive transition for Rigel Pharmaceuticals. The departure of the previous Chief Medical Officer, Dr. Lisa Rojkjaer, and the immediate appointment of Dr. Alison L. Hannah, who was already a member of the company's Board of Directors, indicates a planned leadership change. For a life sciences company, the Chief Medical Officer role is critical for clinical development, regulatory strategy, and pipeline execution. Dr. Hannah's prior experience as a board member and in pharmaceutical development suggests a focus on continuity and strategic alignment, especially following recent major events like the VEPPANU licensing agreement.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RIGL was trading at $38.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $708.4M. The 52-week trading range was $18.24 to $52.24. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.